RENAL AND BONE SAFETY OF TENOFOVIR ALAFENAMIDE VS TENOFOVIR DISOPROXIL FUMARATE

被引：0
|
作者：
Post, Frank [1 ]
Sax, Paul [2 ]
Saag, Michael [3 ]
Yin, Michael [4 ]
Oka, Shinichi [5 ]
Koenig, Ellen [6 ]
Trottier, Benoit [7 ]
Andrade, Jaime [8 ]
Cao, Huyen [9 ]
Fordyce, Marshall [9 ]
机构：
[1] Kings Coll Hosp London, London, England
[2] Brigham & Womens Hosp, Boston, MA 02115 USA
[3] Univ Alabama, Tuscaloosa, AL 35487 USA
[4] Columbia Univ, New York, NY USA
[5] Int Med Ctr Japan, Tokyo, Japan
[6] Dominican Inst Virol Studies, Santo Domingo, Japan
[7] Clin Med Actuel Montreal, Montreal, Dominican Rep
[8] Hosp Civil Guadalajara, Guadalajara, Jalisco, Mexico
[9] Gilead Sci Inc, Foster City, Mexico
来源：
SEXUALLY TRANSMITTED INFECTIONS | 2015年 / 91卷
关键词：
D O I：
10.1136/sextrans-2015-052126.142
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P99
引用
收藏
页码：A48 / +
页数：2
相关论文
共 50 条
  • [31] Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF)
    Seto, Wai Kay Walter
    Buti, Maria
    Izumi, Namiki
    Lim, Young-Suk
    Kao, Jia-Horng
    Streinu-Cercel, Adrian
    Nurmukhametova, Elena
    Ma, Xiaoli
    Tabak, Fehmi
    Jablkowski, Maciej
    Suri, Vithika
    Flaherty, John F.
    Lau, Audrey H.
    Gaggar, Anuj
    Mo, Shuyuan
    Chowdhury, Abhijit
    Fung, Scott K.
    Chuang, Wan-Long
    Gane, Edward J.
    HEPATOLOGY, 2018, 68 : 240A - 241A
  • [32] 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection
    Agarwal, Kosh
    Brunetto, Maurizia
    Seto, Wai Kay
    Lim, Young-Suk
    Fung, Scott
    Marcellin, Patrick
    Ahn, Sang Hoon
    Izumi, Namiki
    Chuang, Wan-Long
    Bae, Ho
    Sharma, Manoj
    Janssen, Harry L. A.
    Pan, Calvin Q.
    Celen, Mustafa Kemal
    Furusyo, Norihiro
    Shalimar, Dr
    Yoon, Ki Tae
    Huy Trinh
    Flaherty, John F.
    Gaggar, Anuj
    Lau, Audrey H.
    Cathcart, Andrea L.
    Lin, Lanjia
    Bhardwaj, Neeru
    Suri, Vithika
    Subramanian, G. Mani
    Gane, Edward J.
    Buti, Maria
    Chan, Henry L. Y.
    JOURNAL OF HEPATOLOGY, 2018, 68 (04) : 672 - 681
  • [33] Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Lee, Hye Won
    Cho, Young Youn
    Lee, Hyein
    Lee, Jae Seung
    Kim, Seung Up
    Park, Jun Yong
    Kim, Do Young
    Ahn, Sang Hoon
    Kim, Beom Kyung
    Park, Soo Young
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (11) : 1570 - 1578
  • [34] Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load
    Baijun Li
    Zhaozhe Liu
    Xing Liu
    Dongchun Liu
    Mingyu Duan
    Ye Gu
    Qiong Liu
    Qiang Ma
    Yushi Wei
    Yan Wang
    Hepatology International, 2021, 15 : 1103 - 1108
  • [35] Clinical Efficacy and Safety of Long-Term Treatment of Tenofovir Alafenamide vs Tenofovir Disoproxil Fumarate for Chronic Hepatitis B in Vietnam
    Nguyen, Thao Huynh Phuong
    Bui, Quynh Thi Huong
    Vo, Thong Duy
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (10)
  • [36] Safety of tenofovir alafenamide in people with HIV who experienced proximal renal tubulopathy on tenofovir disoproxil
    Campbell, Lucy
    Barbini, Birgit
    Cromarty, Ben
    Hamzah, Lisa
    Williams, Deborah
    Winston, Alan
    Post, Frank A.
    AIDS, 2024, 38 (09) : 1442 - 1445
  • [37] Efficacy and safety of tenofovir disoproxil fumarate and tenofovir alafenamide fumarate in preventing HBV vertical transmission of high maternal viral load
    Li, Baijun
    Liu, Zhaozhe
    Liu, Xing
    Liu, Dongchun
    Duan, Mingyu
    Gu, Ye
    Liu, Qiong
    Ma, Qiang
    Wei, Yushi
    Wang, Yan
    HEPATOLOGY INTERNATIONAL, 2021, 15 (05) : 1103 - 1108
  • [38] Early safety of tenofovir alafenamide in patients with a history of tubulopathy on tenofovir disoproxil fumarate: a randomized controlled clinical trial
    Hamzah, L.
    Williams, D.
    Bailey, A. C.
    Jones, R.
    Ibrahim, F.
    Musso, C. G.
    Burling, K.
    Barbini, B.
    Campbell, L.
    Post, F. A.
    Hamzah, Lisa
    Campbell, Lucy
    Adegbaju, Oluwayomi
    Engler, Birgit
    Bhagwandin, Priya
    Santana-Suarez, Beatriz
    Post, Frank
    Johnson, Margaret
    Hemat, Nargis
    Ngwu, Nnenna
    Nightingale, Alice
    Edwards, Jonathan
    Fernandez, Thomas
    Williams, Deborah
    Richardson, Celia
    Campbell, Marion
    Trevitt, Vittorio
    Jones, Rachael
    Fedele, Serge
    Bisdomini, Elisa
    Montauri, Laura
    Thunder, Orla
    Morrish, Thomas
    Soler-Carracedo, Alfredo
    Martinez-Berlanga, Andrea
    Bailey, Angela
    Alagaratnam, Jasmini
    Legg, Ken
    Petersen, Claire
    Clift, Paul
    Cromarty, Ben
    HIV MEDICINE, 2020, 21 (03) : 198 - 203
  • [39] Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back
    Milinkovic, Ana
    Berger, Florian
    Arenas-Pinto, Alejandro
    Mauss, Stefan
    AIDS, 2019, 33 (15) : 2387 - 2391
  • [40] BONE AND RENAL SAFETY OF TENOFOVIR ALAFENAMIDE ( TAF) AT 8 YEARS IN CHRONIC HBV ( CHB) PATIENTS WITH UNDERLYING RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE ( TDF)
    Buti, Maria
    Gane, Edward J.
    Agarwal, Kosh
    Wong, Grace Lai-Hung C.
    Lim, Young-Suk
    Chen, Chi-Yi
    Lim, Seng Gee
    Yatsuhashi, Hiroshi
    Fung, Scott K.
    Abramov, Frida
    Wang, Hongyuan
    Yee, Leland J.
    Flaherty, John F.
    Pan, Calvin Q.
    Marcellin, Patrick
    HEPATOLOGY, 2023, 78 : S507 - S509
12345